Sumary of Biomarker testing decisions for lung cancer vary between academic, community oncologists:
- September 10, 2021 3 min read Source/Disclosures Published by: Source: Boehmer L, et al.
- Back to Healio Considerably fewer community oncology clinicians than academic clinicians use biomarker testing to guide discussions with patients with lung cancer, according to survey results.
- The findings — presented at International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer — showed less than half of respondents in the community setting used biomarker testing to guide patient discussions about prognosis compared with nearly three-quarters of academic clinicians.
- Advocacy groups and professional organizations should help develop impactful education materials and tools for improving clinician-patient conversations about biomarker testing, Boehmer added.
- One section of the report focused on the “imprecision of precision medicine” due partly to limited understanding of the etiology and genetics of cancer within underserved racial and ethnic populations.
- These include environmental factors, access to quality health care, insurance status, patient mistrust of the health care system, and the extent to which clinicians and patients understand the important role biomarker testing can play in treatment decision-making, according to study background.
- “In reality, disparities have only grown related to ability to pay/insurance status for testing, mistrust in the healthcare system, and discordance between patients’ and clinicians’ understanding of the importance of biomarker testing to treatment planning.
- ” Boehmer and colleagues conducted a mixed-methods survey of U.S.-based oncology clinicians attitudes and educational needs regarding biomarker testing.